Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study

Kan Yonemori, Valentina Boni, Kim Gun Min, Tarek Meniawy, Janine Lombard, Peter A. Kaufman, Debra L. Richardson, Laura Bender, Meena Okera, Koji Matsumoto, Karthik V. Giridhar, José Á. García-Sáenz, Hans Prenen, Bernard Doger de Spéville Uribe, Don S. Dizon, Javier Garcia-Corbacho, Els Van Nieuwenhuysen, Yujia Li, Shawn T. Estrem, Bastien Nguyen, Francesca Bacchion, Roohi Ismail-Khan, Komal Jhaveri, Kalyan Banda